AMGN: IRS Dispute And Tax Overhang Will Pressure Future Returns

Narrative Update on Amgen

Analysts have adjusted Amgen's fair value estimate by about $1 to $244.55 as they balance a lower discount rate and slightly higher projected profit margins against more cautious revenue growth assumptions and recent shifts in Street price targets tied to the ramp of Uplizna and ongoing IRS dispute commentary.

Analyst Commentary

Recent Street research on Amgen has been mixed, with some firms raising price targets around the launch of Uplizna in generalized myasthenia gravis and others trimming targets as they factor in tax uncertainty and differing views on long term growth drivers. For you as an investor, the key signals are about how analysts are weighing execution on new therapies against legal and financial overhangs.

Morgan Stanley has highlighted that Uplizna's rollout in generalized myasthenia gravis is off to what it describes as a strong start and sees scope for the broader gMG market to expand materially over the next several years as more biologics and new therapies enter. At the same time, other research points to ongoing scrutiny of Amgen's rare disease portfolio and tax audit exposure, which can feed into more conservative models and valuation ranges.

Bearish Takeaways

Bearish analysts have lowered Amgen price targets, citing the formal IRS audit dispute for 2016 to 2018 and the notice of proposed adjustment, which introduces added uncertainty around future tax payments and could weigh on valuation multiples until there is clearer resolution.
Some research reduces targets even while keeping positive ratings, which signals that upside expectations are more muted and that execution on newer assets like Uplizna, alongside rare disease contributions and programs such as Tepezza, needs to track closely to current assumptions.
Separate bearish adjustments to Amgen price targets in recent months, including cuts from prior target levels, point to concern that Street models may have been too optimistic on aggregate growth and are being recalibrated to reflect a more balanced view of revenue drivers and legal risk.
Investors are also seeing more neutral initiations on Amgen, which indicates that some analysts view the current share price as already reflecting a fair amount of expected growth, leaving less room if execution on new launches or resolution of tax issues is slower than hoped.

What's in the News

Q1 2026 results showed adjusted EPS of $5.15 and revenue of $8.6b, with newer products such as Repatha, TEZSPIRE, TEPEZZA, EVENITY, oncology, rare disease treatments and biosimilars accounting for about 70% of product sales and rising 24% year over year, while legacy drugs like Prolia, Enbrel and Otezla faced pressure and the company raised full year earnings and revenue guidance (source: Amgen Reports Strong Q1 2026 Results).
The FDA has proposed withdrawing approval for Tavneos due to questions over effectiveness and alleged false statements, and Amgen is formally challenging this proposal while commissioning an independent data review and continuing to work with regulators (source: Amgen Reports Strong Q1 2026 Results and Amgen Challenges FDA Proposal to Withdraw Tavneos).
The European Commission granted marketing authorization for Imdelltra (tarlatamab) as a monotherapy for adults with extensive stage small cell lung cancer after platinum based chemotherapy, following Phase 3 data showing a 40% reduction in mortality risk and extended median overall survival versus standard chemotherapy (source: EU Approval for Imdelltra / IMDYLLTRA).
Phase 3 VESALIUS CV data presented at the American Diabetes Association meetings indicated that Repatha, on top of statins or other LDL C lowering therapies, reduced the risk of first major cardiovascular events by 29% in high risk diabetes patients and lowered ischemia driven revascularization risk by 21%, reinforcing Amgen's focus on cardiometabolic conditions (source: Repatha Phase 3 Data in High Risk Diabetes).
Management is presenting at the Jefferies Global Healthcare Conference to outline 2026 growth plans, capital allocation and pipeline priorities, with particular attention on the obesity candidate MariTide and the broader use of AI in R&D, manufacturing and commercial operations (source: Amgen to Present 2026 Growth Plans and Pipeline Advances at Jefferies Healthcare Conference).

Valuation Changes

Fair Value: The fair value estimate has risen slightly from $243.49 to $244.55 per share.
Discount Rate: The discount rate has edged down from 7.67% to 7.57%, reflecting a modestly lower required return in the model.
Revenue Growth: Long term revenue growth assumptions have been reduced, from a prior decline of 7.32% to a steeper assumed decline of 11.63%.
Net Profit Margin: Assumed net profit margin has inched higher from 20.73% to 21.18%, indicating a slightly stronger profitability outlook in the model.
Future P/E: The future P/E multiple has eased from 21.71x to 21.04x, implying a marginally lower valuation multiple applied to forward earnings.

11 views

Key Takeaways

Heavy dependence on aging therapies and patent expirations exposes Amgen to revenue and margin declines amid increasing biosimilar and innovative competition.
Regulatory and pricing pressures, combined with acquisition integration risks and escalating costs, may restrict profitability and challenge sustainable long-term growth.
Expanding product pipeline, operational efficiencies, and secular healthcare trends position Amgen for sustained revenue growth, greater earnings resilience, and improved long-term profitability.

Catalysts

About Amgen

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.What are the underlying business or industry changes driving this perspective?

The company faces mounting pressure from prospective drug pricing reforms and the progressive adoption of value-based care models, which are likely to constrain its pricing power and limit long-term revenue growth as payors become less willing to reimburse for expensive branded therapies.
Despite strong short-term volume growth, Amgen's overreliance on aging blockbuster drugs such as Enbrel, combined with looming patent cliffs and accelerating biosimilar competition in both core and emerging markets, threatens significant revenue erosion and gross margin compression over time.
The growing risk of government-imposed price controls or reference pricing, particularly in the U.S. and key international markets, may act as a cap on future profitability, placing long-term limitations on both earnings expansion and free cash flow generation.
Intensifying competition from innovative biotech and large pharmaceutical companies-with novel modalities including gene therapies, mRNA treatments, and next-generation obesity drugs (including orally delivered GLP-1s)-poses a risk to Amgen's future market share, slowing the ramp-up of new products and leading to potential stagnation or contraction in top-line growth.
Large-scale acquisitions such as Horizon Therapeutics introduce the potential for integration challenges and increased operational leverage, which, when coupled with sharply rising R&D and capital expenditures, could strain net margins and shareholder returns if new product launches fail to offset pressures from patent expirations and deteriorating pricing environments.

Amgen Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

This narrative explores a more pessimistic perspective on Amgen compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts.
The bearish analysts are assuming Amgen's revenue will remain fairly flat over the next 3 years.
The bearish analysts assume that profit margins will increase from 21.0% today to 21.2% in 3 years time.
The bearish analysts expect earnings to reach $7.9 billion (and earnings per share of $14.45) by about June 2029, up from $7.8 billion today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as $12.7 billion.
In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 21.1x on those 2029 earnings, down from 24.6x today. This future PE is greater than the current PE for the US Biotechs industry at 16.5x.
The bearish analysts expect the number of shares outstanding to grow by 0.25% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.57%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Amgen is experiencing strong, broad-based volume and revenue growth across multiple therapeutic areas, including double-digit sales growth for 15 products and a 9% year-over-year increase in total revenue, which may drive further top-line and earnings expansion.
The company's robust late-stage pipeline-including promising assets in obesity (MariTide), rare diseases, cardiovascular medicine, oncology, and a strong bispecific T cell engager (BiTE) platform-positions Amgen for meaningful new product launches, supporting long-term revenue diversification and profit growth.
Strategic focus and leading execution in biosimilars, as evidenced by 40% year-over-year sales growth and a successful track record in launches and regulatory approvals, could significantly bolster Amgen's revenues and improve operational margins as more high-revenue biologics lose patent protection.
Ongoing investments in artificial intelligence, automation, and R&D, paired with disciplined financial management, are driving greater operating efficiency and free cash flow, which could underpin resilient net margins and long-term profitability.
Secular trends such as an aging global population, rising prevalence of chronic and rare diseases, and expanding demand for personalized and biologic medicines provide enduring tailwinds, likely increasing utilization of Amgen's portfolio and supporting long-term revenue and earnings growth.

Valuation

How have all the factors above been brought together to estimate a fair value?

The assumed bearish price target for Amgen is $244.55, which represents up to two standard deviations below the consensus price target of $352.5. This valuation is based on what can be assumed as the expectations of Amgen's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $427.0, and the most bearish reporting a price target of just $200.0.
In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2029, revenues will be $37.1 billion, earnings will come to $7.9 billion, and it would be trading on a PE ratio of 21.1x, assuming you use a discount rate of 7.6%.
Given the current share price of $355.2, the analyst price target of $244.55 is 45.2% lower.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Amgen?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystLowTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystLowTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystLowTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Aging Blockbusters And Pricing Pressures Will Erode Profitability